Webinars & Presentations

The critical role of a flexible, reproducible and scalable technology for cellular engineering in the rapid development of protein therapeutics.

Video presentation – From the ASGCT 25th Annual meeting held on May 16th in Washington DC

iONTAS’s innovative antibody discovery technology can save time and effort downstream by addressing antibody developability issues during the initial phase of biotherapeutic discovery.

Targeted locus amplification (TLA) to identify genomic sites of transgene integration and transgene sequence integrity to assess the suitability of recombinant CHO clones for the generating of candidate therapeutic proteins pre-clinical studies.

Parallel track large-scale transient expression and rapid stable clone generation in biomanufacturing relevant cells by integrating MaxCyte’s electroporation technology into biotherapeutic development programs.

MaxCyte scalable transient transfection enables high quality, biologically relevant cellular assays that can take assay development off the critical path. – April 24, 2013

Express quality, bioactive bispecific antibodies, BITEs, tribodies, and full IgGs in CHO cells using a consistent, scalable electroporation technology.

Combining high capacity electroporation and automated patch clamp recording to overcome barriers to functional annotation of human variants in voltage-gated ion channels.

September 17, 2020 – Peter Gee – MaxCyte Field Application Scientist – CRISPR-Cas9 has tremendous potential as a therapeutic tool for treating human diseases. However, prolonged expression of the nuclease and gRNA from viral vectors in an in vivo context may cause unwanted off-target activity and immunogenicity. To overcome these safety issues, a system was recently developed for transient delivery of CRISPR-Cas9 ribonucleoprotein (RNP), recruiting Cas9 protein by chemically-induced dimerization and sgRNA via a viral RNA packaging signal into extracellular nanovesicles.